I am a
Home I AM A Search Login

Papers of the Week

Papers: 19 Nov 2022 - 25 Nov 2022

2022 Dec

Lancet Neurol



Safety and efficacy of continuous subcutaneous foslevodopa-foscarbidopa in patients with advanced Parkinson’s disease: a randomised, double-blind, active-controlled, phase 3 trial.


Soileau MJ, Aldred J, Budur K, Fisseha N, Fung V S, Jeong A, Kimber TE, Klos K, Litvan I, O'Neill D, Robieson WZ, Spindler MA, Standaert DG, Talapala S, Vaou E O, Zheng H, Facheris MF, Hauser RA
Lancet Neurol. 2022 Dec; 21(12):1099-1109.
PMID: 36402160.


Levodopa is the most effective symptomatic therapy for Parkinson's disease, but patients with advanced Parkinson's disease develop motor fluctuations with chronic oral levodopa therapy. Foslevodopa-foscarbidopa is a soluble formulation of levodopa and carbidopa prodrugs that is delivered as a 24-h/day continuous subcutaneous infusion, and we aimed to assess the safety and efficacy of this formulation in patients with advanced Parkinson's disease.